HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in primary tumor specimens and metastatic disease using an osteosarcoma tumor microarray (TMA) (n = 62). The association of HHLA2 with the presence of tumor infiltrating lymphocytes (TILs) and five-year-event-free-survival were examined. HHLA2 was expressed in 68% of osteosarcoma tumors. HHLA2 was expressed in almost all metastatic disease specimens and was more prevalent than in primary specimens without known metastases (93% vs 53%, p = 0.02). TILs were present in 75% of all osteosarcoma specimens. Patients whose tumors were ≥25% or ≥50% HHLA2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%, p = 0.02). Overall, we have shown that HHLA2 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival. Along with previously reported findings that HHLA2 is a T cell co-inhibitor, these results suggest that HHLA2 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Another inhibitory molecule HHLA2, a newly defined B7 family member, widely expressed in osteosarcoma, which is associated with metastases and worse survival [100].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Translational biology of osteosarcoma
Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Self-citationvan Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Perry, J. A., Kiezun, A., Tonzi, P., Van Allen, E. M., Carter, S. L., Baca, S. C., Cowley, G. S., Bhatt, A. S., Rheinbay, E., Pedamallu, C. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419260111 · Cited by 481
Osteosarcoma: a review of diagnosis, management, and treatment strategies.
Geller, D. S., & Gorlick, R. G. (2010) · PubMed · Cited by 475
Self-citationObjective Measurement and Clinical Significance of TILs in Non–Small Cell Lung Cancer
Schalper, K. A., Brown, J., Carvajal-Hausdorf, D., McLaughlin, J., Velcheti, V., Syrigos, K. N., Herbst, R. S., & Rimm, D. L. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju435 · Cited by 417
The Molecular Pathogenesis of Osteosarcoma: A Review
Broadhead, M. L., Clark, J. C. M., Myers, D. E., Dass, C. R., & Choong, P. F. M. (2011) · Sarcoma · doi:10.1155/2011/959248 · Cited by 346
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 336
Self-citationKoirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S., Hoang, B. H., Park, A., Fremed, M. A., Zang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep30093 · Cited by 267
Self-citationBielack, S. S., Kempf-Bielack, B., Branscheid, D., Carrle, D., Friedel, G., Helmke, K., Kevric, M., Jundt, G., Kühne, T., Maas, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2305 · Cited by 238 · cited 1×
“Median age years (SD) 16 (22) 19 (20) 16 (4)”
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function
Zhao, R., Chinai, J. M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H., Ohaegbulam, K. C., Ghosh, K., Zhao, A., Scharff, M. D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303524110 · Cited by 208
Self-citationEnhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Lussier, D. M., O’Neill, L., Nieves, L. M., McAfee, M. S., Holechek, S. A., Collins, A. W., Dickman, P., Jacobsen, J., Hingorani, P., & Blattman, J. N. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000065 · Cited by 197
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Shen, J. K., Cote, G. M., Choy, E., Yang, P., Harmon, D., Schwab, J., Nielsen, G. P., Chebib, I., Ferrone, S., Wang, X., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0224 · Cited by 193
Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy
Champiat, S., Ferté, C., Lebel-Binay, S., Eggermont, A., & Soria, J. C. (2014) · OncoImmunology · doi:10.4161/onci.27817 · Cited by 192
B7-H5 costimulates human T cells via CD28H
Zhu, Y., Yao, S., Iliopoulou, B. P., Han, X., Augustine, M. M., Xu, H., Phennicie, R. T., Flies, S. J., Broadwater, M., Ruff, W., et al. (2013) · Nature Communications · doi:10.1038/ncomms3043 · Cited by 186
Janakiram, M., Chinai, J. M., Fineberg, S., Fiser, A., Montagna, C., Medavarapu, R., Castano, E., Jeon, H., Ohaegbulam, K. C., Zhao, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1495 · Cited by 154
Self-citationMager, D. L., Hunter, D. G., Schertzer, M. J., & Freeman, J. (1999) · Genomics · doi:10.1006/geno.1999.5877 · Cited by 149
Hawkins, D. S., & Arndt, C. A. S. (2003) · Cancer · doi:10.1002/cncr.11799 · Cited by 147
Chromothripsis: Chromosomes in Crisis
Jones, M. J. K., & Jallepalli, P. V. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.10.010 · Cited by 130
HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families
Janakiram, M., Chinai, J. M., Zhao, A., Sparano, J. A., & Zang, X. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1026534 · Cited by 117 · cited 1×
“Median age years (SD) 16 (22) 19 (20) 16 (4)”
Self-citationKubo, T., Piperdi, S., Rosenblum, J., Antonescu, C. R., Chen, W., Kim, H., Huvos, A. G., Sowers, R., Meyers, P. A., Healey, J. H., et al. (2008) · Cancer · doi:10.1002/cncr.23437 · Cited by 112
Self-citationFlajnik, M. F., Tlapáková, T., Criscitiello, M. F., Krylov, V., & Ohta, Y. (2012) · Immunogenetics · doi:10.1007/s00251-012-0616-2 · Cited by 92
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
Abdeen, A., Chou, A. J., Healey, J. H., Khanna, C., Osborne, T. S., Hewitt, S. M., Kim, M., Wang, D., Moody, K., & Gorlick, R. (2009) · Cancer · doi:10.1002/cncr.24562 · Cited by 77
Self-citationIdentification of IGPR-1 as a novel adhesion molecule involved in angiogenesis
Rahimi, N., Rezazadeh, K., Mahoney, J. E., Hartsough, E., & Meyer, R. D. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-11-0934 · Cited by 65
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
Xiao, Y., & Freeman, G. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2658 · Cited by 53
Evaluation of eIF4E Expression in an Osteosarcoma-Specific Tissue Microarray
Osborne, T. S., Ren, L., Healey, J. H., Shapiro, L. Q., Chou, A. J., Gorlick, R. G., Hewitt, S. M., & Khanna, C. (2011) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e318223d0c1 · Cited by 25
Self-citationBiofunctions of three new B7 family members (IRM7P.486)
Wang, J., Manick, B., Wu, G., & Hao, R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.192.supp.126.11 · Cited by 10 · cited 1×
“Median age years (SD) 16 (22) 19 (20) 16 (4)”
Research works printed but not linked: 1
- Shen J. K. et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2, 690– 698, doi: 10.1158/2326-6066.CIR-13-0224 (2014). 24866169 PMC4082476 · DOI · Paper page
Cited by
Advancing therapy for osteosarcoma
Gill, J., & Gorlick, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00519-8 · Cited by 876
Self-citationAdvances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Another inhibitory molecule HHLA2, a newly defined B7 family member, widely expressed in osteosarcoma, which is associated with metastases and worse survival [100].”
BackgroundNew B7 Family Checkpoints in Human Cancers
Ni, L., & Dong, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0761 · Cited by 244
“B7-H7 is expressed in the majority of osteosarcoma tumors and its expression is associated with metastatic disease and poorer survival, suggesting that B7-H7 may be a novel immunosuppressive mechanism within the osteosarcoma tumor microenvironment (103).”
BackgroundThe third group of the B7‐CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3
Janakiram, M., Shah, U. A., Liu, W., Zhao, A., Schoenberg, M. P., & Zang, X. (2017) · Immunological Reviews · doi:10.1111/imr.12521 · Cited by 225
Self-citationJing, C., Fu, Y., Yi, Y., Zhang, M., Zheng, S.-S., Huang, J., Gan, W., Xu, X., Lin, J., Zhang, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0554-8 · Cited by 128
Metadata
- Authors
- Koirala, P., Roth, M. E., Gill, J., Chinai, J. M., Ewart, M. R., Piperdi, S., Geller, D. S., Hoang, B. H., Fatakhova, Y. V., Ghorpade, M., Zang, X., & Gorlick, R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Zang, Xingxing
- Gorlick, Richard
- Venue
- Scientific Reports
- Published
- 2016-08-17
- Volume
- 6
- Issue
- 1
- Pages
- 31154-31154
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4987662
- OpenAlex
- W2517687042
- Cited by
- 100
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 16 · 2023: 14 · 2022: 11 · 2021: 15 · 2020: 9 · 2019: 12 · 2018: 7 · 2017: 4 · 2016: 1
- FWCI
- 7.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (PC131008)
- Swim Across America
- National Institutes of Health (5k12ca132783-12, 1s10od019961-01)
- National Cancer Institute (K12-CA132783, R01CA175495)
- National Institute of General Medical Sciences (T32GM007288)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100525)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
- Keywords
- HHLA2, B7 family, osteosarcoma, immune checkpoint, metastasis, tumor-infiltrating lymphocytes, event-free survival, tumor microenvironment, immunosuppression, T cell co-inhibition
- MeSH terms
- Adolescent, Adult, Bone Neoplasms, Child, Female, Humans, Immunoglobulins, Male, Prognosis, Osteosarcoma, Biomarkers, Tumor, Lymphocytes, Tumor-Infiltrating, Disease-Free Survival, Protein Array Analysis, Kaplan-Meier Estimate, Young Adult, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.